Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Soliris
Biotech
Novartis touts new budding disease med as it battles AstraZeneca
Novartis is touting expanded data of its phase 3-stage rare disease med as it takes on a couple of AstraZeneca gems.
Max Bayer
Dec 13, 2022 10:00am
Novartis takes another swipe at AstraZeneca's rare disease gems
Dec 8, 2022 10:28am
AstraZeneca's danicopan improves hemoglobin levels in phase 3
Sep 16, 2022 9:40am
CANbridge posts early-phase data on rival to AstraZeneca drug
Feb 7, 2022 8:35am
Novartis posts Soliris rival data, aims to be standard of care
Aug 31, 2020 8:15am
Genentech posts long-term data on near-approval Soliris rival
May 22, 2020 8:50am